- Home
- MESO vs INBX Comparison
MESO vs INBX Comparison
Compare MESO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MESO | INBX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MESO | INBX |
|---|---|---|
| Price | $11.96 | $89.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $37.00 | ★ $266.67 |
| AVG Volume (30 Days) | ★ 216.6K | 197.1K |
| Earning Date | 08-26-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $59.17 | N/A |
| Revenue Next Year | $59.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $12.94 | $28.16 |
| 52 Week High | $21.50 | $155.29 |
Technical Indicators
Market Signals| Indicator | MESO | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 28.02 | 38.85 |
| Support Level | N/A | $85.65 |
| Resistance Level | $15.97 | $99.33 |
| Average True Range (ATR) | 0.40 | 4.66 |
| MACD | -0.12 | -0.50 |
| Stochastic Oscillator | 2.03 | 26.74 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.